ASPG and acute lymphoblastic leukemia: Out of the seven patients with VTE for whom peg-asparaginase was discontinued or dose reduced, three (37.5%) developed progression of ALL compared with progression in two (18%) of the 11 patients in which peg-asparaginase was continued after VTE (p = .52).